M4K Pharma Open Scientific Update Meeting May 2018- Recording Full recording from M4K Pharma's Scientific Update Meeting - May 9th, 2018. Listen to our scientists and collaborators discuss the latest progress in M4K Pharma's quest for a medicine for DIPG- a deadly children's brain cancer. Everyone is invited to dial-in and join [...]
Video recording of M4K’s April Scientific Update meeting Catch M4K Pharma’s virtual Scientific Update Meeting from April 6th, 2018 where our scientists and collaborators discussed the latest progress in our Medicines4Kids project for diffuse intrinsic pontine gliomas (DIPG).
[Podcast] Bio2040 interviews M4K Pharma's Owen Roberts In a podcast interview with Bio2040, CEO Owen Roberts discusses M4K Pharma's business model and why open science and sharing can be the path to finding medicines for rare diseases like DIPG.
SGC Open Notebookers support DIPG drug discovery by sharing their research on ALK2 in real-time In January 2018, a group of post-doctoral fellows at the Structural Genomics Consortium (SGC) undertook the bold task of sharing their real-time and unpolished experimental results through open lab notebooks online in a mission to facilitate collaboration and transparency [...]
Video recording of M4K's March Scientific Update meeting! Listen to M4K Pharma's virtual Scientific Update Meeting from March 7th, 2018 where our scientists and collaborators discussed the latest progress in M4K's Medicines4Kids project for diffuse intrinsic pontine gliomas (DIPG). Everyone is invited to see the chemistry first-hand! https://youtu.be/Ip-2QVhmhZc
Editorial: Research community ready for Open Source Drug Discovery In an Editorial to the Canadian Science Policy Centre, Drs. Aled Edwards and Aidan Hollis describe the need for Open Source Drug Discovery to address the inefficiencies in developing new drugs and the resulting exorbitant prices of new medicines. The support for M4K [...]
Making medicine, not money: How one U of T researcher's startup is rethinking Big Pharma's business model M4K Pharma's first target is a rare childhood brain cancer that's just as deadly as it was 50 years ago From U of T News (November 3, 2017) The latest medical innovation to [...]
